Mr. Ye Yin – CEO
Ye Yin, is committed to promoting the application of advanced biomedical and genomic technologies in clinical practice in order to reduce birth defect rates and curb the incidence of major diseases, with the overall goal of improving human health.
Mr Yin joined BGI in 2002. He has served sequentially as research fellow of IVD and genome research, President of BGI-Tech, and Chief Operating Officer of BGI. During this period, he has led the starting up of BGI’s global sales and marketing team, established BGI’s global research and production facilities, and guided the globalization of the Chinese company. Mr Yin was appointed CEO of BGI Genomics Co. Ltd in 2015.
Academically, he has led or participated in more than one hundred international genome research projects and has a long list of publications in top ranked journals.